

# Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France

Marie Herr, Helene Grondin, Stéphane Sanchez, Didier Armaingaud, Caroline Blochet, Antoine Vial, Philippe Denormandie, Joël Ankri

# ▶ To cite this version:

Marie Herr, Helene Grondin, Stéphane Sanchez, Didier Armaingaud, Caroline Blochet, et al.. Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France. European Journal of Clinical Pharmacology, 2017, 73 (5), pp.601 - 608. 10.1007/s00228-016-2193-z. inserm-01802839

# HAL Id: inserm-01802839 https://inserm.hal.science/inserm-01802839

Submitted on 29 May 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Polypharmacy and potentially inappropriate medications: a cross-sectional analysis among 451 nursing homes in France

Running head: Suboptimal prescribing in nursing homes

Marie Herr<sup>1,2,3</sup>\*, Helene Grondin<sup>1,2</sup>, Stéphane Sanchez<sup>4,5</sup>, Didier Armaingaud<sup>6</sup>, Caroline Blochet<sup>7</sup>, Antoine Vial<sup>8</sup>, Philippe Denormandie<sup>5</sup>, Joël Ankri<sup>1,2,3</sup>

<sup>1</sup> INSERM, U1168, VIMA: Aging and chronic diseases. Epidemiological and public health approaches, Villejuif, F-94807, France

<sup>2</sup> Univ Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180, Montigny le Bretonneux, France

<sup>3</sup> Département Hospitalier d'Epidémiologie et de Santé Publique, Hôpital Sainte Périne, APHP, Paris, France

<sup>4</sup> Pôle Information Médicale Evaluation Performance, Centre Hospitalier de Troyes, Troyes, France

<sup>5</sup> Institut du Bien Vieillir, Paris, France

<sup>6</sup> Korian, Paris, France

<sup>7</sup> Medissimo, Poissy, France

<sup>8</sup> AVL, Paris, France

\* Corresponding author: Marie Herr

UMR 1168, UFR des Sciences de la Santé Simone Veil, 2 avenue de la source de la Bièvre, 78180 Montigny-le-Bretonneux, France ; marie.herr@uvsq. fr ; +33170429251

Funding: This research did not receive any specific grant from funding agencies in the public,

commercial, or not-for-profit sectors.

Conflict of interest statement: None to declare

Acknowledgments: We would like to thank Medissimo and Mr Olivier Desnoux for the data

extraction.

Word count: 2,729

2

#### Abstract

<u>Purpose:</u> The quality of drug therapy is an important issue for nursing homes. This study aimed to assess the prevalence of polypharmacy and potentially inappropriate medications (PIMs) in a large sample of nursing home residents by using the data recorded during the preparation of pill dispensers.

Methods: This is a cross-sectional study that included 451 nursing homes across France. Information about the medications received by the 30,702 residents (73.8% women) living in theses nursing homes was extracted from the system that assists the preparation of pill dispensers in pharmacies. The anonymized database included age, sex, and medications prescribed to residents, as well as nursing home characteristics (capacity, legal status). Factors associated with excessive polypharmacy (≥10 different drugs) and PIMs according to the Laroche list were studied using multilevel regression models.

Results: The average number of drugs prescribed was 6.9 +/- 3.3 and excessive polypharmacy concerned 21.1% of the residents (n=6,468). According to the Laroche list, 47.4% of residents (n=14,547) received at least one PIM. Benzodiazepines (excessive doses, long-acting benzodiazepines, and combination of benzodiazepines) and anticholinergic medications (hydroxizine, cyamemazine, alimemazine) accounted for a large part of PIMs. Individual characteristics (age, gender) influenced the risk of receiving PIMs whereas nursing home characteristics (capacity, legal status) influenced the risk of excessive polypharmacy.

<u>Conclusions:</u> This study shows that polypharmacy and PIMs remain highly prevalent among nursing home residents. Main PIMs concerned psychotropic and anticholinergic medications.

<u>Key words:</u> aged, frail elderly, inappropriate prescribing, information system, nursing homes, polypharmacy

#### Introduction

As people live longer, they accumulate health problems and drug prescriptions. The addition of medications increases the risk of adverse drug effects and of drug-drug and drug-disease interactions [1,2]. Polypharmacy was shown to be the main determinant of iatrogenic effects of medications [3,4]. In addition, age-associated changes in body composition (sarcopenia) and organ function (decrease in renal and metabolic clearance) can cause changes in the pharmacokinetic/pharmacodynamics properties of medications, and hence modify the safety profile of medications [5].

In order to avoid adverse drug reactions in older people, the benefit-risk balance of each drug should be considered, as well as the risk of interactions. Lists of Potentially Inappropriate Medications (PIMs) were published to help adapt the drug regimen in older people, notably the Beers' criteria, which were first published in 1991 to assess medication appropriateness in nursing homes [6]. Reasons for inappropriateness include an unfavorable benefit-risk ratio, the absence of clear indication or efficacy [7]. This list had been updated several times [8,9] and other lists have been developed, notably to have guidelines that take into account the national specificities in terms of commercialized drugs and practices. In France, Laroche et al published a French list of PIMs in 2007 [10]. This list included 34 general criteria and 5 additional criteria where the PIM is related to an underlying condition.

Studies that compared drug regimen between institutionalized people and old people living in community have shown higher rates of polypharmacy and PIMs among institutionalized people [11-13]. Inappropriate drug use was shown to increase the risk of adverse health outcomes (hospitalizations, emergency department visits, death) in nursing home residents [14-16]. The quality of drug therapy is an important issue for nursing homes and the use of psychotropic medications and polypharmacy have been proposed as indicators of quality of care in nursing homes [17,18]. Indicators of the quality of drug therapy should be monitored

regularly to identify areas for improvement and evaluate the efficacy of interventions. Data about drug therapy in nursing homes can be retrieved from medical records but also from insurance claims and pill dispenser systems. These last options should develop with the increasing willingness of stakeholders involved in health and quality of care to share their data for quality purposes.

In this context, this study aimed to describe the drugs' prescriptions of old people living in nursing homes in terms of polypharmacy and PIMs, by using the data collected during the preparation of pill dispensers.

#### Material and methods

Study design and population

This is a cross-sectional study that analyzed the drugs prescribed to the 30,702 persons living in the 451 nursing homes that used a pill dispenser supplied by the company Medissimo (Poissy, France) at the time of the analysis. The pill dispenser contains 28 days of treatment, with as many compartments as drugs and time of administration. It is prepared by qualified staff in pharmacy. During the preparation, information about the individuals and their prescriptions is entered in specific software to ensure traceability. Although the pharmaceutical forms that cannot be placed in the pill dispenser (sachets, creams, drops, etc.) are given in their original packaging, information about these drugs are still recorded in the information system. Data from March 25<sup>th</sup> to March 31<sup>st</sup> 2014 were extracted from the information system and communicated anonymously to the UMR 1168 for analysis. Medissimo received the approval of the National Commission for Data Protection and Liberties (CNIL, authorization n°1067312).

Data

The database included the following information:

- Residents: sex, month and year of birth;
- Drugs: Anatomical Therapeutical Classification (ATC) code, dosage, time and date of administration; Nursing homes: legal status (public, private not-for-profit, private for-profit) and capacity (number of places).

# Indicators of suboptimal prescribing

The number of drugs prescribed was determined for each day of the week. In order to take into account drugs administered weekly (for instance bisphosphonates), the assessment of polypharmacy considered the day of the week where the number of medications was the most important. Polypharmacy was defined as five medications or more and excessive polypharmacy as 10 medications or more. This definition included systemic drugs, as well as topical ones.

PIMs were those listed in the Laroche list [10]. Briefly, the French panel consensus list is based on the 2003 Beers criteria but several drugs or therapeutic drug classes were not selected, because they were not available on the French market (such as mataxalone, guanabenz, barbiturates, except phenobarbital) or because the drugs were not judged inappropriate by the French experts (such as amiodarone and nonsteroidal anti-inflammatory drugs, except indometacine). Conversely, some criteria were added to the Beers criteria, notably the concomitant use of two (or more) nonsteroidal anti-inflammatory drugs and the concomitant use of two (or more) psychotropic drugs from the same therapeutic class. The drugs or the drug-classes proposed in this list are to be avoided when possible in the elderly, because of questionable efficacy and/or of unfavorable benefit-risk ratio. We excluded the 5 criteria that required information about underlying conditions because the database did not include clinical information.

# Statistical analyses

Indicators of suboptimal prescribing were described in terms of prevalence. Factors related to excessive polypharmacy and to the fact of receiving at least one PIM were investigated among variables related to residents (age and sex) and nursing homes (legal status and capacity) by using Chi-2 test. Multilevel logistic regression models were used to study the independent effect of each variable, with an individual level and a nursing home level in order to take into account the correlation between subjects of a same nursing home. Indeed, the intraclass correlation coefficient obtained in empty models indicated that 8.0% and 3.4% of the total variance of excessive polypharmacy and of at least one PIM was explained by the nursing home level respectively. Analyses were performed using Stata® software v13 and the level of significance was set at 5%.

#### Results

#### **Population**

Of the 451 included nursing homes, 57.7% were private-for-profit (n=260), 29.9% were private-not-for-profit (n=135), and 12.4% were public facilities (n=56). The mean number of places per nursing home was  $85 \pm 7$  33. Residents included 22,655 women (73.8%) and 8,047 men (26.2%). After exclusion of 904 potentially erroneous values of age considering the context (i.e. age 60 = 110), the mean age was  $87.4 \pm 7.6$ . The mean number of drugs prescribed was  $6.9 \pm 3.3$ . The most prescribed drugs are listed in the Table 1.

Polypharmacy, PIMs, and anticholinergic drugs

Polypharmacy (5 to 9 medications) and excessive polypharmacy (≥10 medications) concerned 54.9% (n=16,854) and 21.1% (n=6,468) of the residents respectively. Potentially

inappropriate prescribing was found in 14,547 residents (47.4%). PIMs and their rationale are listed by order of frequency in the Table 2. Additional information about drugs participating in the different PIMs is given in Appendix 1. Psychotropic medications were a leading cause of PIMs, because of inappropriate dosage, molecule or association. Notably, 2,876 residents (9.4%) received at least two different benzodiazepines during the study period. The prescription of drugs with anticholinergic properties was another frequent PIM. Considered together, drugs with anticholinergic properties were prescribed in 12.2% of the residents (n=3,738). Among them, hydroxyzine was largely prescribed, in 3.4% of the residents (n=1,217). Other notable PIMs involved antihypertensive drugs (4.6% of the residents, n=1,415), cerebral vasodilators and muscle relaxants, especially baclofene.

#### Factors associated with suboptimal prescribing

Factors associated with suboptimal prescribing are described in Table 3. Men and older residents were at lower risk of PIMs. Private for-profit nursing homes had lower levels of excessive polypharmacy compared to public nursing homes, as well as intermediate- size compared to small- size nursing homes. Overall, individual characteristics influenced the risk of receiving PIMs whereas nursing home characteristics influenced the risk of excessive polypharmacy.

#### **Discussion**

#### Main findings

Taking advantage of technologies used to secure the administration of drugs in nursing homes, indicators of quality of drug therapy could be calculated in a large population of nursing home residents. Excessive polypharmacy and PIMs concerned a large part of the

study population, 21.1% and 47.4% respectively. Areas for improvement mostly concerned psychotropic and anticholinergic medications.

# **Polypharmacy**

The prevalence of excessive polypharmacy found in this study was close to the estimate of the SHELTER study. Among voluntary nursing homes in 7 European countries + Israel, the prevalence of excessive polypharmacy was 24.3% [19]. The health outcomes associated with polypharmacy in old people living in community have been extensively studied. Risks associated with polypharmacy include falls, hospitalizations, and mortality [20,21]. In the context of nursing homes, polypharmacy has been recognized as a major cause of adverse drug events [22], notably falls [23]. The increased risk of adverse drug events associated with polypharmacy may be explained by the increased risk of receiving psychotropic medications and PIMs. In addition, polypharmacy increases medication regimen complexity and the risk of errors during the preparation and dispensation of medications [24].

#### **PIMs**

The prevalence of PIMs was relatively high compared to studies in community that reported a prevalence of PIMs about 20% [25,26]. Comparison with other studies that assessed PIMs in nursing homes is complicated by methodological differences between studies regarding the PIMs criteria and data source. The literature shows that the prevalence of PIMs in nursing homes varies widely between studies, from 15% to 89% [27,28]. Two studies previously used the Laroche list [10] in the context of nursing homes and reported prevalence of PIMs about 22% [29,30]. Our higher estimate (47.4%) can be explained by differences in the number of criteria considered. Indeed, the prevalence reported by Cool et al in 175 nursing homes in the South region of France refers to medications with unfavorable benefit-risk ratio only, PIMs

due to questionable efficacy being considered separately [29]. In the German study by Kolzsch et al, the authors could not identify overdosing of benzodiazepines and concomitant use of drugs from a same therapeutic class, whereas these criteria accounted for a large part of the PIMs in our study population [30]. More generally, our estimate is in line with a recent review of literature that estimated the prevalence of PIMs in nursing homes at 49.8% (all criteria of PIMs considered, studies published since 2005) [31].

Psychotropic and anticholinergic medications accounted for a large part of PIMs in this study. Though there are clear national and international recommendations to avoid the use of long-acting benzodiazepines in old people [32,8,33,10], they were still prescribed in 7.2% of the residents in the present study. Among benzodiazepine users, those receiving long-acting molecules were shown to be at increased risk of falls [34,35]. Furthermore, long-acting benzodiazepines would increase the risk of onset of dementia assumed in benzodiazepine users [36]. The use of excessive doses of short- or intermediate- half-life benzodiazepines, as well as the prescription of multiple benzodiazepines, was another worrying result. Though to a lower extent compared to long-acting molecules, short- and intermediate- half-life benzodiazepines also increase the risk of adverse effects such as cognitive impairment, delirium, drowsiness, and falls [10,37]. Moreover, the combination of several psychotropics does not necessarily ameliorate the symptoms, and may increase the risk of interactions and side-effects [38].

Using data from reimbursement of medications in 2012, Beuscart et al reported that 22.3% of people living in nursing homes in the North region of France received anticholinergic drugs, hydroxyzine in two third of the cases [39]. Though anticholinergic drugs were far less prescribed in our study (12.2%), hydroxyzine was still the most prescribed anticholinergic drug, probably because it is considered an alternative to benzodiazepines in the treatment of anxiety. However, drugs with anticholinergic properties can cause peripheral side effects such

as dry mouth and constipation, as well as central side effects, namely falls, dizziness, delirium, and cognitive decline [40].

# Factors associated with suboptimal prescribing

The increased risk of PIMs observed in women is quite surprising. Indeed, gender had no influence on PIMs in any of the 11 studies that studied this relationship [12,41,30,42-44,29,45,46,14,47]. This result may reflect the fact that women live longer, but with a heavier burden of comorbidity, and hence medications. Though we did not confirm the inverse association between excessive polypharmacy and age previously found in the SHELTER study [19], we observed a significant decrease in the prevalence of PIMs with advanced age, consistently with previous studies in nursing homes [12,48,49,30,15,44]. This phenomenon may be explained by the reduction of pharmacotherapy in people with limited life expectancy, especially in demented people who are less likely to receive PIMs according to the literature [14, 15, 16, 29, 40, 43, 46].

Contrary to the results published by Beers et al in 1992 that reported an increased risk of PIMs among large nursing homes [6], we found that intermediate- size nursing homes had lower rates of polypharmacy and PIMs compared to small ones. In addition, private-for-profit nursing homes had lower rates of polypharmacy compared to public nursing homes. These results indicate that organizational factors can play a role in the quality of drug prescribing. In a qualitative study in long-term aged care, Tariq et al actually identified multiple system-related factors that could influence the risk of prescribing errors [50]. They were related to communication systems, team coordination and staff management. Organizational differences between nursing homes should be further investigated in order to identify levers to reduce PIMs. Emphasis should be given to the communication between staff and doctors who come

to visit their patients in the nursing home and to the implementation of comprehensive geriatric evaluation and multidisciplinary medication review [51].

### Strengths and limitations of the study

The main strength of this study is the size of the study population, covering 6.6% of the total number of places in nursing homes in France [52]. All the nursing homes using the pill dispenser Mono28® were included in this study. This is hence a real life evaluation of the quality of drug therapy, as opposed to studies in samples of nursing homes willing to participate where a selection bias can be expected. Nevertheless, the included nursing homes were not representative of French nursing homes in terms of legal status. Indeed, the proportion of private-for-profit nursing homes was higher in our study sample compared to national statistics (58% versus 43%) and the proportion of public nursing homes was lower (12% versus 26%). The mean capacity of the included nursing homes was comparable to national statistics (85 places versus 83 places).

The use of multi dose systems to assess medications in nursing homes can restrict information to tablets and capsules that can be placed in the multi dose system [12]. Because information was collected during the preparation of all the medications prescribed in the pharmacy, this study overcame this limitation and provided information about other formulations than tablets and capsules (inhalers, sachets, drops, syrups, injectable, etc.). Moreover, information was sufficiently detailed to allow the assessment of PIMs based on inappropriate dosage. Nevertheless, we did not have information about the health and diseases of the residents. This prevented us from studying drug-disease interactions. However, an underestimation of the overall prevalence of PIMs in this study because of the exclusion of drug-disease interactions is unlikely because most of the criteria of the Laroche list [10] that consider drug-disease interactions deal with the prescription of anticholinergic drugs (e.g. drugs with anticholinergic

properties in patients with prostate closed-angle glaucoma or chronic constipation), which are also considered in other criteria.

Though the choice to use the Laroche list [10] was the most relevant with regards to the French context, this list has not been updated since its publication in 2007. Many drugs had been withdrawn from the market since then and maybe some other recommendations could be added. For instance, several studies have recently been published concerning the adverse effects of prolonged use of proton-pump inhibitors (fractures, pneumonia, death) [53], resulting in their inclusion in the 2015 update of the Beers criteria [9]. Considering the high prevalence of use of proton-pump inhibitors in the study population (esomeprazole was used by 17% of the included residents), a part of misuse is likely.

Because data were collected during the routine process of preparation of the pill dispensers by the pharmacy staff and not by trained investigators, we registered about 2.9% of abnormal values of age. These individuals had to be excluded from multivariate analyses. Nevertheless, they did not differ from the rest of the study population in terms of mean number of medications prescribed. Errors regarding medications are very unlikely because the pill dispenser once prepared is checked by a pharmacist.

# Conclusion

By using the data collected in routine during the preparation of pill dispensers for nursing homes, this study shows that excessive polypharmacy and inappropriate prescribing concern a large part of nursing home residents. Further studies are required 1/ to understand individual and organizational factors associated with suboptimal prescribing and 2/ to assess the consequences of each criteria of suboptimal prescribing, in terms of adverse health outcomes and subsequent costs, in order to refine the list of indicators of quality of drug therapy and operationalize their monitoring.

#### References

- 1. Fialova D, Onder G (2009) Medication errors in elderly people: contributing factors and future perspectives. Br J Clin Pharmacol 67 (6):641-645. doi:10.1111/j.1365-2125.2009.03419.x
- 2. Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, Auger JC, Garber LA, Cadoret C, Fish LS, Garber LD, Kelleher M, Bates DW (2004) Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 52 (8):1349-1354. doi:10.1111/j.1532-5415.2004.52367.x
- 3. O'Mahony D, Cherubini A, Petrovic M (2012) Optimizing pharmacotherapy in older patients: a European perspective. Drugs Aging 29 (6):423-425. doi:2 [pii]

#### 10.2165/11630990-0000000000-00000

- 4. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289 (9):1107-1116. doi:joc21714 [pii]
- 5. Shi S, Morike K, Klotz U (2008) The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64 (2):183-199. doi:10.1007/s00228-007-0422-1
- 6. Beers MH, Ouslander JG, Fingold SF, Morgenstern H, Reuben DB, Rogers W, Zeffren MJ, Beck JC (1992) Inappropriate medication prescribing in skilled-nursing facilities. Annals of internal medicine 117 (8):684-689

- 8. American Geriatrics Society Beers Criteria Update Expert P (2012) American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60 (4):616-631. doi:10.1111/j.1532-5415.2012.03923.x
- 9. Counsell SR (2015) 2015 updated AGS Beers Criteria offer guide for safer medication use among older adults. Geriatric nursing 36 (6):488-489
- 10. Laroche ML, Charmes JP, Merle L (2007) Potentially inappropriate medications in the elderly: a French consensus panel list. Eur J Clin Pharmacol 63 (8):725-731. doi:10.1007/s00228-007-0324-2
- 11. Barnett K, McCowan C, Evans JM, Gillespie ND, Davey PG, Fahey T (2011) Prevalence and outcomes of use of potentially inappropriate medicines in older people: cohort study stratified by residence in nursing home or in the community. BMJ quality & safety 20 (3):275-281. doi:10.1136/bmjqs.2009.039818
- 12. Halvorsen KH, Granas AG, Engeland A, Ruths S (2012) Prescribing quality for older people in Norwegian nursing homes and home nursing services using multidose dispensed drugs. Pharmacoepidemiology and drug safety 21 (9):929-936. doi:10.1002/pds.2232
- 13. Haasum Y, Fastbom J, Johnell K (2012) Institutionalization as a risk factor for inappropriate drug use in the elderly: a Swedish nationwide register-based study. The Annals of pharmacotherapy 46 (3):339-346. doi:10.1345/aph.1Q597
- 14. Perri M, 3rd, Menon AM, Deshpande AD, Shinde SB, Jiang R, Cooper JW, Cook CL, Griffin SC, Lorys RA (2005) Adverse outcomes associated with inappropriate drug use in nursing homes. The Annals of pharmacotherapy 39 (3):405-411. doi:10.1345/aph.1E230

- 16. Lau DT, Kasper JD, Potter DE, Lyles A, Bennett RG (2005) Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Archives of internal medicine 165 (1):68-74. doi:10.1001/archinte.165.1.68

  17. Frijters DH, van der Roest HG, Carpenter IG, Finne-Soveri H, Henrard JC, Chetrit A, Gindin J, Bernabei R (2013) The calculation of quality indicators for long term care facilities in 8 countries (SHELTER project). BMC health services research 13:138. doi:10.1186/1472-6963-13-138
- 18. Zimmerman DR (2003) Improving nursing home quality of care through outcomes data: the MDS quality indicators. Int J Geriatr Psychiatry 18 (3):250-257. doi:10.1002/gps.820 19. Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, Gallo PF, Carpenter I, Finne-Soveri H, Gindin J, Bernabei R, Landi F, Project S (2012) Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci 67 (6):698-704. doi:10.1093/gerona/glr233
- 20. Fried TR, O'Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK (2014) Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 62 (12):2261-2272. doi:10.1111/jgs.13153
- 21. Herr M, Robine JM, Pinot J, Arvieu JJ, Ankri J (2015) Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiology and drug safety 24 (6):637-646. doi:10.1002/pds.3772
- 22. Nguyen JK, Fouts MM, Kotabe SE, Lo E (2006) Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 4 (1):36-41. doi:10.1016/j.amjopharm.2006.03.002
- 23. Morley JE (2014) Inappropriate drug prescribing and polypharmacy are major causes of poor outcomes in long-term care. Journal of the American Medical Directors Association 15 (11):780-782. doi:10.1016/j.jamda.2014.09.003

- 24. Witticke D, Seidling HM, Lohmann K, Send AF, Haefeli WE (2013) Opportunities to reduce medication regimen complexity: a retrospective analysis of patients discharged from a university hospital in Germany. Drug Saf 36 (1):31-41. doi:10.1007/s40264-012-0007-5

  25. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K (2015) Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol 71 (12):1415-1427. doi:10.1007/s00228-015-1954-4

  26. Opondo D, Eslami S, Visscher S, de Rooij SE, Verheij R, Korevaar JC, Abu-Hanna A (2012) Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PloS one 7 (8):e43617. doi:10.1371/journal.pone.0043617

  27. Blozik E, Born AM, Stuck AE, Benninger U, Gillmann G, Clough-Gorr KM (2010) Reduction of inappropriate medications among older nursing-home residents: a nurse-led, pre/post-design, intervention study. Drugs Aging 27 (12):1009-1017. doi:10.2165/11584770-0000000000-00000
- 28. Grace AR, Briggs R, Kieran RE, Corcoran RM, Romero-Ortuno R, Coughlan TL, O'Neill D, Collins R, Kennelly SP (2014) A comparison of beers and STOPP criteria in assessing potentially inappropriate medications in nursing home residents attending the emergency department. Journal of the American Medical Directors Association 15 (11):830-834. doi:10.1016/j.jamda.2014.08.008
- 29. Cool C, Cestac P, Laborde C, Lebaudy C, Rouch L, Lepage B, Vellas B, Barreto Pde S, Rolland Y, Lapeyre-Mestre M (2014) Potentially inappropriate drug prescribing and associated factors in nursing homes. Journal of the American Medical Directors Association 15 (11):850 e851-859. doi:10.1016/j.jamda.2014.08.003
- 30. Kolzsch M, Bolbrinker J, Huber M, Kreutz R (2010) [Potentially inappropriate medication for the elderly: adaptation and evaluation of a French consensus list]. Medizinische Monatsschrift für Pharmazeuten 33 (8):295-302

- 31. Morin L, Laroche ML, Texier G, Johnell K (2016) Prevalence of Potentially Inappropriate Medication Use in Older Adults Living in Nursing Homes: A Systematic Review. Journal of the American Medical Directors Association 17 (9):862 e861-869. doi:10.1016/j.jamda.2016.06.011
- 32. Benzodiazépine à demi-vie longue chez le sujet âgé. Haute Autorité de Santé. (2012). http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-
- 05/3\_ipc\_bzd\_demi\_vie\_long\_sa\_octobre\_2011.pdf. Accessed June 2016
- 33. Lang PO, Hasso Y, Belmin J, Payot I, Baeyens JP, Vogt-Ferrier N, Gallagher P, O'Mahony D, Michel JP (2009) [STOPP-START: adaptation of a French language screening tool for detecting inappropriate prescriptions in older people]. Can J Public Health 100 (6):426-431
- 34. Ray WA, Thapa PB, Gideon P (2000) Benzodiazepines and the risk of falls in nursing home residents. J Am Geriatr Soc 48 (6):682-685
- 35. Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R, Silver Network Home Care Study G (2005) Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 60 (5):622-626
- 36. Pariente A, de Gage SB, Moore N, Begaud B (2016) The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge. CNS drugs 30 (1):1-7. doi:10.1007/s40263-015-0305-4
- 37. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2012). J Am Geriatr Soc 60:616-631
- 38. Gulla C, Selbaek G, Flo E, Kjome R, Kirkevold O, Husebo BS (2016) Multi-psychotropic drug prescription and the association to neuropsychiatric symptoms in three Norwegian

- nursing home cohorts between 2004 and 2011. BMC Geriatr 16 (1):115. doi:10.1186/s12877-016-0287-1
- 39. Beuscart JB, Dupont C, Defebvre MM, Puisieux F (2014) Potentially inappropriate medications (PIMs) and anticholinergic levels in the elderly: a population based study in a French region. Archives of gerontology and geriatrics 59 (3):630-635. doi:10.1016/j.archger.2014.08.006
- 40. Gerretsen P, Pollock BG (2011) Drugs with anticholinergic properties: a current perspective on use and safety. Expert opinion on drug safety 10 (5):751-765. doi:10.1517/14740338.2011.579899
- 41. Hosia-Randell HM, Muurinen SM, Pitkala KH (2008) Exposure to potentially inappropriate drugs and drug-drug interactions in elderly nursing home residents in Helsinki, Finland: a cross-sectional study. Drugs Aging 25 (8):683-692
- 42. Stafford AC, Alswayan MS, Tenni PC (2011) Inappropriate prescribing in older residents of Australian care homes. Journal of clinical pharmacy and therapeutics 36 (1):33-44. doi:10.1111/j.1365-2710.2009.01151.x
- 43. Chen LL, Tangiisuran B, Shafie AA, Hassali MA (2012) Evaluation of potentially inappropriate medications among older residents of Malaysian nursing homes. International journal of clinical pharmacy 34 (4):596-603. doi:10.1007/s11096-012-9651-1
- 44. Mann E, Haastert B, Bohmdorfer B, Fruhwald T, Iglseder B, Roller-Wirnsberger R, Meyer G (2013) Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents: secondary analysis of a cross-sectional study. Wiener klinische Wochenschrift 125 (7-8):180-188. doi:10.1007/s00508-013-0342-2
- 45. Lao CK, Ho SC, Chan KK, Tou CF, Tong HH, Chan A (2013) Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in

- Macao. International journal of clinical pharmacy 35 (5):805-812. doi:10.1007/s11096-013-9811-y
- 46. Vieira de Lima TJ, Garbin CA, Garbin AJ, Sumida DH, Saliba O (2013) Potentially inappropriate medications used by the elderly: prevalence and risk factors in Brazilian care homes. BMC Geriatr 13:52. doi:10.1186/1471-2318-13-52
- 47. Zuckerman IH, Hernandez JJ, Gruber-Baldini AL, Hebel JR, Stuart B, Zimmerman S, Magaziner J (2005) Potentially inappropriate prescribing before and after nursing home admission among patients with and without dementia. Am J Geriatr Pharmacother 3 (4):246-254
- 48. Bergman A, Olsson J, Carlsten A, Waern M, Fastbom J (2007) Evaluation of the quality of drug therapy among elderly patients in nursing homes. Scandinavian journal of primary health care 25 (1):9-14. doi:10.1080/02813430600991980
- 49. Niwata S, Yamada Y, Ikegami N (2006) Prevalence of inappropriate medication using Beers criteria in Japanese long-term care facilities. BMC Geriatr 6:1. doi:10.1186/1471-2318-6-1
- 50. Tariq A, Georgiou A, Raban M, Baysari MT, Westbrook J (2015) Underlying risk factors for prescribing errors in long-term aged care: a qualitative study. BMJ quality & safety. doi:10.1136/bmjqs-2015-004589
- 51. Burns E, McQuillan N (2011) Prescribing in care homes: the role of the geriatrician. Therapeutic advances in chronic disease 2 (6):353-358. doi:10.1177/2040622311421438
- 52. Les soins en EHPAD en 2013 : le financement de la médicalisation et le bilan des coupes Pathos. Caisse Nationale de Solidarité pour l'Autonomie. (2014). http://www.uriopss-pacac.asso.fr/resources/trco/pdfs/2014/J\_octobre\_2014/79559soins\_en\_ehpad\_en\_2013.pdf. Accessed June 2016

53. Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Butto V, Ferrucci L, Bandinelli S, Abbatecola AM, Spazzafumo L, Lattanzio F (2013) Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA internal medicine 173 (7):518-523. doi:10.1001/jamainternmed.2013.2851

Table 1. List of the most prescribed drugs in the 30,702 residents included in the study

Drug's name	N (%)		
Acetaminophen	10,964 (35.7)		
Aspirin	9,517 (31.0)		
Macrogol	6,588 (21.5)		
Furosemide	6,576 (21.4)		
Esomeprazole	5,225 (17.0)		
Levothyroxin	4,297 (14.0)		
Potassium choride	3,903 (12.7)		
Zopiclone	3,764 (12.3)		
Escitalopram	3,693 (12.0)		
Bisoprolol	3,563 (11.6)		
Oxazepam	3,516 (11.5)		
Alprazolam	3,172 (10.3)		
Associations containing calcium	3,116 (10.2)		

Table 2. Prevalence of potentially inappropriate medications (PIMs) in the 30,702 residents included in the study

PIM Reason		N (%)	
Dose of short- or intermediate- half-life	Questionable efficacy and increased	5,371 (17.5)	
benzodiazepines > half the dose given in	risk of cognitive impairment,		
young subjects	delirium, drowsiness, falls		
Use of two or more psychotropic drugs from	Questionable efficacy and increased	4060 (13.2)	
the same therapeutic class during the study	risk of adverse effects		
period			
Long-acting benzodiazepines	Increased risk of cognitive	2,199 (7.2)	
	impairment, delirium, drowsiness,		
	falls		
Anticholinergic histamines	Anticholinergic effects	1,256 (4.1)	
Short-acting calcium-channel blockers	May cause postural hypotension,	1044 (3.4)	
	myocardial infarction, and stroke		
Anticholinergic antipsychotic drugs	Anticholinergic effects, second choice	891 (2.9)	
	drugs		
Anticholinergic antidepressants	Anticholinergic effects, potential for	639 (2.1)	
	cardiotoxicity, second-choice drugs		
Anticholinergic hypnotic drugs	Anticholinergic effects	614 (2.0)	
Anticholinergic antispasmodic drugs	Anticholinergic effects	531 (1.7)	
Cerebral vasodilators	Questionable efficacy	442 (1.4)	
Centrally acting antihypertensives	Sedation, hypotension, bradycardia,	412 (1.3)	

	syncope	
Muscle relaxants	Sedation, falls	318 (1.0)
Concomitant use of anticholinesterase drugs	Antagonistic mechanisms	280 (0.9)
and drugs with anticholinergic properties		
Antiarythmics	Unfavorable benefit-risk ratio of	194 (0.6)
	digoxine > 0.125 mg/j and	
	disopyramide	
Other drugs with anticholinergic properties:	Anticholinergic effects and	161 (0.5)
antiemetics, cough suppressants, nasal	questionable efficacy	
decongestants, or antidrowsiness drugs		
Nitrofurantoïne	Potential for pulmonary toxicity and	89 (0.3)
	lack of efficacy in case of renal failure	
Stimulant laxatives	Worsening of irritable bowel	38 (0.1)
	syndrome	
Gastrointestinal antispasmodic drugs with	Anticholinergic effects and	26 (0.1)
anticholinergic properties	questionable efficacy	
Dipyridamole	May cause orthostatic hypotension	10 (0.0)
	and more-effective	
	alternatives available	
Use of two or more non-steroidal anti-	No enhancement of efficacy and	8 (0.0)
inflammatory drugs during the study period	increased risk of adverse effects	
Long-acting sulfonylureas	Prolonged hypoglycemia	8 (0.0)
Ticlopidine	Blood and hepatic adverse effects	4 (0.0)

Cimetidine	Confusion, drug-drug interactions	4 (0.0)
Reserpine	Drowsiness, depression,	0
	gastrointestinal disorders	

Table 3. Factors associated with suboptimal prescribing in the 28,600 residents included in the multivariate analysis

Variable	Excessive polypharmacy			At least one PIM		
	N (%) <sup>a</sup>	aOR <sup>b</sup> (95%CI)	p	N (%)	aOR <sup>b</sup> (95%CI)	p
Gender						
Women	4,787 (21.1)	1		10,829 (47.8)	1	
Men	1,681 (26.0)	1.00 (0.94-1.07)	0.927	3,718 (46.2)	0.87 (0.82-0.91)	< 0.001
Age (tertiles, years)						
60-85.5	2,143 (21.4)	1		5,379 (53.6)	1	
85.6-91.1	2,090 (21.2)	0.99 (0.92-1.06)	0.824	4,442 (45.0)	0.70 (0.66-0.74)	< 0.001
91.2 and over	2,070 (21.0)	0.99 (0.93-1.07)	0.822	4,245 (42.9)	0.64 (0.60-0.67)	< 0.001
Legal status of the nursing						
home						
Public	855 (22.7)	1		1,837 (48.7)	1	
Private not-for-profit	1,981 (22.6)	0.96 (0.79-1.16)	0.658	4,202 (48.0)	0.94 (0.82-1.08)	0.353
Private-for-profit	3,632 (20.0)	0.81 (0.68-0.98)	0.026	8,508 (46.8)	0.93 (0.82-1.08)	0.255
Number of places in the						
nursing home						
1-78	2,334 (22.7)	1		4,987 (48.4)	1	
79-94	2,041 (19.8)	0.83 (0.72-0.95)	0.006	4,824 (46.8)	0.94 (0.85-1.03)	0.173
95-242	2,091 (20.7)	0.92 (0.80-1.06)	0.243	4,724 (46.8)	0.94 (0.85-1.04)	0.509

<sup>&</sup>lt;sup>a</sup> Prevalence of excessive polypharmacy and PIM according to individual and organizational factors. For instance, the prevalence of excessive polypharmacy is 21.1% among women and 26.0% among men.

<sup>&</sup>lt;sup>b</sup> Odds Ratio of the multilevel logistic regression model adjusted for all the variables included in the table.